Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Innovation Endeavors
Deal Size : $8.7 million
Deal Type : Financing
BioLoomics Raises $8.7 Million Seed Round to Develop Target Degrading Antibodies
Details : The net proceeds will be used to advance company's proprietary platform technology and antibody degrader programs and to develop pre-clinical assets and form strategic partnerships with large pharma companies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 19, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Innovation Endeavors
Deal Size : $8.7 million
Deal Type : Financing